Disease · MONDO_0008383

rheumatoid arthritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rheumatoid arthritis. Diseases, record MONDO_0008383. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008383

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rheumatoid arthritis; Open Targets
Open Targets ID: MONDO_0008383; Open Targets
Other names: Arthritis or polyarthritis, rheumatic, Arthritis, Rheumatoid, Chronic rheumatic arthritis, Proliferative arthritis, RA, RA - Rheumatoid arthritis, RhA - Rheumatoid arthritis, Rheumatic gout, Rheumatoid arthritis (disorder), Rheumatoid arthritis NOS, Rheumatoid arthritis NOS (disorder), Rheumatoid disease, atrophic Arthritis; Open Targets
Disease Ontology: DOID:7148; Disease Ontology
MeSH: D001172; MeSH
NCI Thesaurus: C2884; NCI Thesaurus
Orphanet: ORPHA:284130; Orphanet
Highest stage of its drugs: Approval, for 81 of its 454 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs454

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	265	254	254	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	162	154	154	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD	164	134	131	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Approval	DailyMed, EMA Human Drugs and PMDA	127	114	112	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Approval	DailyMed and EMA Human Drugs	104	92	91	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	80	76	76	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	84	71	71	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Approval	EMA Human Drugs and TTD	64	60	60	Drugs and targets
CERTOLIZUMAB PEGOL	CHEMBL1201831	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	47	44	44	Drugs and targets
SARILUMAB	CHEMBL2108730	Antibody	Approval	DailyMed, EMA Human Drugs, FDA, PMDA and TTD	33	27	27	Drugs and targets

1 to 10 of 454

See all 454 drugs

Targets332

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	31	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	21	Cyclooxygenase inhibitor; Cyclooxygenase-1 inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
NR3C1	Glucocorticoid receptor	17	Glucocorticoid receptor agonist; Glucocorticoid receptor modulator	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
MAPK14	Mitogen-activated protein kinase 14	16	MAP kinase p38 alpha inhibitor	Phase 2	https://conductscience.org/library/genes/1432	Drugs and targets
JAK1	Janus Kinase (JAK)	11	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
TNF	Tumor necrosis factor	11	TNF-alpha binding agent; TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
BTK	TEC family kinase	10	TEC family kinase inhibitor; Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
JAK3	Janus Kinase (JAK)	10	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
JAK2	Janus Kinase (JAK)	9	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
TYK2	Janus Kinase (JAK)	8	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Approval	https://conductscience.org/library/genes/7297	Drugs and targets

1 to 10 of 332

See all 332 targets

Trials1,276

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 25 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00346216	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	Phase 4	24,081	2017-05-01	Arthritis, Rheumatoid	CELECOXIB, IBUPROFEN, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT06418529	A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis		21,340	2025-07-31	Rheumatoid Arthritis	ABATACEPT, TOCILIZUMAB, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01932372	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis		9,968	2024-10-26	Rheumatoid Arthritis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01646385	Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry		6,393	2014-08-05	Rheumatoid Arthritis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00488475	Observational Trial With Enbrel		4,945	2014-05-15	Rheumatoid Arthritis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00413699	Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis	Phase 3	4,488	2018-03-27	Arthritis, Rheumatoid	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT00141102	Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis	Phase 4	4,484	2010-06-11	Osteoarthritis, Arthritis, Rheumatoid	CELECOXIB, DICLOFENAC, OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02092467	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	Phase 4	4,372	2021-08-17	Arthritis, Rheumatoid	ADALIMUMAB, ETANERCEPT, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT00234884	Post-marketing Observational Study in Subjects With Rheumatoid Arthritis		3,435	2011-09-30	Rheumatoid Arthritis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00975130	Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)	Phase 3	3,366	2012-12-07	Arthritis, Rheumatoid	GOLIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,276

See all 1,276 trials

Comparisons in its trials390

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Etanercept vs nbDMARDs: serious adverse events	944 of 3,529	744 of 2,864	6,393	NCT01646385	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)	20 of 2,238	81 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms	132 of 2,238	162 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs	5 of 2,238	11 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)	25 of 2,238	92 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Withdrawn Due to GI Adverse Events (AEs)	114 of 2,238	167 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: serious adverse events	61 of 2,223	61 of 2,237	4,460	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin	45 of 2,184	123 of 2,167	4,351	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview	82 of 2,047	79 of 2,048	4,095	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Alive at the Post Trial Interview	2,018 of 2,047	2,023 of 2,048	4,095	NCT00141102	Trial comparisons

1 to 10 of 390

See all 390 comparisons in its trials

Papers from its trials1,000

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42263998	RESULT	2	PubMed
39874233	RESULT	1	PubMed
39146891	RESULT	1	PubMed
39061843	RESULT	1	PubMed
38049981	RESULT	1	PubMed
37108584	RESULT	1	PubMed
36675041	RESULT	1	PubMed
36377584	RESULT	1	PubMed
36369238	RESULT	1	PubMed
36335684	RESULT	1	PubMed

1 to 10 of 1,000

See all 1,000 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008383

GET https://conductscience.org/api/diseases/v1/MONDO_0008383/drugs?page=2

API reference For AI assistants